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Abstract 
Purpose: In patients with large total blood volume contrast material (CM) dilution 
decreases coronary attenuation in CT coronary angiography (CTCA). As increased 
blood volume is well paralleled by body surface area (BSA) we assessed a BSA-
adapted CM protocol to compensate for dilution effects. 
Methods: Low-dose CTCA with prospective ECG-triggering was performed in 80 patients 
with a BSA-adapted CM bolus ranging 40 to 105 ml and injection rate ranging 3.5 to 5.0 
ml/sec for a BSA of < 1.70 m2 to ≥2.5 m2. Eighty control patients matched for BSA who 
had previously undergone routine CTCA with a fixed CM protocol of 80 ml at 5ml/sec 
served as reference group. The average vessel attenuation from the proximal right (RCA) 
and the left main coronary artery (LMA) was assessed. Correlation of BSA with vessel 
attenuation was assessed in both groups. 
Results: BSA-matching of all patients was successful (BSA-adapted group 
1.980.15 m2, range 1.66-2.39 m2 vs. reference group 1.980.17 m2, range 1.59-2.38 
m2; P=0.74). Mean CM bolus was significantly smaller in the BSA-adapted vs. the 
reference group (70.914.1 ml vs. 80.00 ml, P<0.001). There was no correlation in 
the BSA-adapted group (r= -0.07, P=0.53, SEE=0.15), while coronary attenuation 
was inversely related to BSA in the reference group (r= -0.59, P<0.001, SEE=0.14).  
Conclusions: We have successfully validated a BSA-adapted contrast material 
protocol which results in a comparable coronary contrast enhancement independent 
of individual BSA. This was achieved despite a significant reduction in the overall 
contrast material amount.  
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Introduction 
Coronary artery disease (CAD) is one of the major causes of morbidity and mortality 
in western countries. Computed tomography coronary angiography (CTCA) is a lately 
introduced non-invasive cardiac imaging method, which has been shown to reliably 
detect significant CAD (greater than 50% luminal narrowing) [1]. Prospective ECG-
triggering has allowed to substantially reduce radiation dose of CTCA from about 15 
to 20 mSv down to 1 to 3 mSv at maintained image quality [2] and accuracy [3, 4] so 
that the clinical acceptance of CTCA is growing. Coronary vessel attenuation may 
affect the accuracy of CTCA [5-7] as for an accurate detection of coronary plaque an 
appropriate amount of contrast material (CM) is needed. While coronary vessels can 
not be differentiated properly from the surrounding tissue with too little CM, coronary 
blooming artefacts caused by too large CM amounts may hamper the detection of 
coronary plaque.  
The attenuation of coronary vessel is influenced by the individual patients 
weight, height (expressed by body mass index (BMI) and body surface area (BSA)) 
and cardiac output [8-13], as well as by technical factors related to the type and 
iodine concentration of the CM [7], the technique for bolus timing [6], the injection 
volume and rate [14], and tube voltage [15]. Previous CTCA protocols [2, 16-18] did 
not adapt to patients individual body mass or cardiac output. Consequently, vessel 
attenuation in CTCA has been shown to vary strongly [6-9], depending on BMI and to 
affect the optimal detection of coronary plaque. Recently a BMI adapted protocol was 
introduced in order to reduce the impact of BMI on image noise. However, coronary 
contrast remained subject to large variations [19], presumably due to bolus dilution 
depending on blood volume. As increased blood volume is well paralleled by BSA we 
identified BSA as the most promising parameter to be of potential value for adjusting 
the contrast bolus in future protocols. Therefore we aimed at assessing a BSA-
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adapted CM protocol to compensate for dilution effects and the interindividual BSA-
related differences in coronary attenuation.  
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Methods 
Patients 
Eighty patients underwent for clinical indication a 64-slice CTCA using 
prospective ECG-triggering with a contrast material protocol adapted to BSA (Table 
1). For comparison, a control group of 80 patients matched for BSA were 
retrospectively recruited from a pool of patients (n=230) who had previously 
undergone CTCA with prospective ECG-gating and a fixed CM protocol of 80 ml. 
Exclusion criteria for CTCA were: hypersensitivity to iodinated CM, renal insufficiency 
(creatinine levels >150 µmol/L), non-sinus rhythm, or haemodynamic instability. 
All 160 patients were referred for evaluation of known (n=23) or unknown CAD 
(n=137), based on symptoms such as dyspnoea (n=18), typical angina pectoris 
(n=27), atypical chest pain (n=75), or without symptoms for pre-operative rule-out of 
CAD in high-risk patients (n=40).  
The study protocol was approved by the institutional review board (local ethics 
committee of the University Hospital Zurich) and written informed consent was 
obtained from each patient.  
 
Body surface area  
BSA is an index which is widely used in clinical practice. For many clinical 
purposes BSA is a better indicator of metabolic mass than body weight because it is 
less affected by abnormal adipose mass. To obtain the BSA (m2) we divided the 
square root of  (height x weight) by 60 as previously reported by Mosteller [20] as this 
is the most widely used method recommended by most authorities including the 
British Columbia Cancer Agency for calculating chemotherapy dosage [21]. 
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Data acquisition and image analysis 
To achieve a target heart rate <65 bpm, intravenous metoprolol (5 to 20 mg) 
(Beloc, AstraZeneca, London, UK) was administered prior to the CTCA examination 
if necessary. Furthermore, all patients received 2.5 mg isosorbiddinitrate sublingual 
(Isoket, Schwarz Pharma, Monheim, Germany) 2 min prior to the scan for which 
iodixanol (Visipaque 320, 320 mg/mL, GE Heathcare, Buckinghamshire, UK) 
followed by 50 ml saline solution was injected into an antecubital vein via an 18-
gauge catheter. Amount and flow rate of CM were gradually increased (40 - 105 ml, 
3.5 – 5.0 ml/sec, corresponding to an iodine delivery rate ranging from 1.1 g/sec to 
1.6 g/sec) to parallel increases in BSA in the BSA-adapted scanning protocol group 
(Table 1a), while in the non-adapted scanning protocol group the amount and flow 
rate of contrast material were kept constant at 80 ml and 5 ml/sec (iodine delivery 
rate 1.6 g/sec). Bolus tracking was performed and image acquisition was started as 
soon as the CM appeared in the ascending aorta, where the region of interest was 
placed.  
All CTCA examinations were performed on a 64-slice LightSpeed VCT XT 
scanner (GE Healthcare) with prospective ECG-triggering, using the following 
scanning parameters: slice acquisition 64 × 0.625 mm, smallest x-ray window (only 
75% of the RR-cycle), z-coverage 40 mm with an increment of 35 mm, gantry 
rotation time 350 ms. Tube voltage and current were adapted to BMI as previously 
described [2] to avoid increases in noise due to increased BMI (Table 1b). The total 
effective radiation dose was calculated by multiplying the dose length product 
(provided by the scanner) times a conversion factor (0.017mSv/cGy/cm) as 
previously suggested [22]. All images were analyzed on an external workstation (AW 
4.4, GE Healthcare).  
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Vessel attenuation (in Hounsfield units, HU) were measured twice by two 
independent readers (A.P. and L.H., both experience level 3 [23]) in the proximal 
RCA and the LMA, which served as regions of interest (ROI) drawn as large as 
possible, carefully avoiding calcifications, plaques, and stenoses, as previously 
described in detail [8]. The mean of the measurements by both readers in both ROI’s 
was defined as “coronary vessel attenuation” and used for further analysis.  
 
Statistical analysis 
All statistical analysis was performed using SPSS software (SPSS 15.0, 
Chicago, ILL, USA). Quantitative variables were expressed as mean ± standard 
deviation (SD), and categorical variables were expressed as frequencies and 
percentages. Differences between the two groups regarding coronary artery 
attenuation and amount of applied contrast material were tested for significance by 
using Mann-Whitney-U-tests. Linear regression analysis was performed to correlate 
BSA and coronary artery attenuation, and multiple regression analysis was 
performed to compare this relationship between both groups. Standard error of the 
estimate (SEE) was determined. A P-value of <0.05 was considered to indicate 
statistical significance. 
 9 
Results 
CTCA was successfully performed in all 160 patients. Baseline characteristics 
of all patients included in this study are given in Table 2. BSA-matching of all patients 
was successful (BSA-adapted group 1.980.15 m2, range 1.66-2.39 m2 vs. reference 
group 1.980.17 m2, range 1.59-2.38 m2; P=n.s.).  
As part of their baseline medication, 40 of 160 patients (25%) were on beta 
blocker treatment. To achieve a target heart rate < 65 bpm intravenous metoprolol 
was given prior to CTCA in 103 patients (64%). The mean dose length product from 
CTCA was 13943 mGycm (range 65-318 mGycm) resulting in an estimated mean 
effective radiation dose of 2.40.7 mSv (range 1.1-3.9 mSv).  
Mean of the interobserver differences (between L.H. and A.P.) in coronary 
artery attenuation measurements was 7.0±23.9 HU. In the BSA-adapted group, 
mean attenuation values from both readers were 37856 HU (range 262 to 490 HU) 
for LMA and 36349 HU (range 260 to 510 HU) for RCA, resulting in a mean 
coronary vessel attenuation of 37049 HU (range 268 to 500 HU). In the non-
adapted group, mean attenuation values were 424110 HU (range 280 to 712 HU) 
for LMA and 413103 HU (range 248 to 688 HU) for RCA, resulting in a mean 
coronary vessel attenuation of 418104 HU (range 264 to 700 HU).  
Coronary attenuation was inversely related to BSA in the reference group (r= -
0.59, P<0.001, SEE=84.6), while there was no correlation in the BSA-adapted group 
(r= -0.07, P=n.s, SEE=49.5) (Fig. 1). 
 The mean applied amount of CM was significantly lower in the BSA-adapted 
vs. the reference group (70.914.1 ml vs. 80.00, P<0.001). 
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Discussion 
The findings of the present study document that the BSA-adapted CM 
administration protocol is feasible and successful as the inverse correlation between 
BSA and coronary attenuation found in our control group, and also documented in 
previous reports [13, 19], could be abolished. As a result, range and standard 
deviation of coronary attenuation were smaller in the BSA-adapted group compared 
to the control group indicating a well balanced consistent contrast enhancement 
throughout a large range of BSA (Fig. 2). Furthermore, by using the BSA-adapted 
protocol a significantly lower average amount of contrast medium was injected, which 
may help preventing contrast induced nephropathy and its sequelae [24]. Although 
the resulting average coronary attenuation was slightly lower than in controls, the 
range of  coronary attenuation obtained with our protocol (300 – 400 HU) compares 
well to the values suggested by Becker et al (250 – 300 HU) [5] and Cademartiri et al 
(>300 HU) [7] for adequate coronary visualization and optimal stenosis detection 
even in relatively small coronary arteries.  
Attenuation of coronary vessel in CTCA is closely related to several factors including 
patient specific characteristics on one side such as body mass, blood volume and 
cardiac output [8, 9, 11, 13] as well as protocol related parameters on the other side 
such as concentration and injection rate of the administered CM [7, 19, 25]. In 
patients with increased body mass CTCA image quality is degraded by an 
unfavorable shift in the signal-to-noise ratio due to increase in noise and loss of 
attenuation. Introduction of scan protocols with body mass index-adapted tube 
current and voltage have allowed to overcome the adverse effects of body mass on 
image noise [25]. By contrast, the adverse effect of body mass on coronary 
attenuation is less well understood but recent reports have suggested increased CM 
dilution due to higher blood volume as explanation. Consequently, the hypothesis 
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has been generated that BSA would be the most promising parameter to be used for 
CM protocol adjustment [13, 19]. Our study provides the evidence to approve this 
hypothesis. As our protocol has included BMI adaptation of tube current and voltage, 
our results suggest that an ideal protocol should integrate both BMI adaptation of 
tube parameters (noise minimization) and CM adjustment according to BSA (signal 
optimization). This may help differentiating coronary plaque from surrounding tissue 
and avoid blooming artefacts caused by excursive intracoronary CM concentration.  
 
We acknowledge the following limitations to the present study: First, the case 
matching of the control group was retrospective, which may have introduced bias. 
Second, the determination of the BSA-adapted contrast material protocol was 
arbitrary.  However, the protocol was designed based on the upslope of the coronary 
attenuation – BSA curve previously reported [19]. Third, coronary attenuation was 
measured only in two proximal vessels (RCA and LMA). However, smaller vessel 
diameters of distal segments do not allow appropriate placing of a ROI. Further 
studies in larger populations are needed to confirm the added value of greater 
consistency in coronary artery attenuation regarding the accuracy of CTCA.  
 
The proposed BSA-adapted contrast material protocol results in an adequate 
coronary vessel attenuation independent of individual BSA. 
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Fig. 1: Linear regression of body surface area against coronary artery 
attenuation 
Linear regression analysis (with 95% confidence interval lines) of body surface area 
(BSA) against coronary artery attenuation in the groups scanned with the BSA-
adapted protocol (left panel) and with the non-adapted contrast material protocol 
(right panel). The significant inverse correlation documented with the non-adapted 
protocol disappears after adapting for BSA. 
 
 
Fig. 2:  CTCA images in patients with different body surface area  
CTCA images of patients with low (< 1.8 m2), intermediate (1.8 – 2.2 m2) and high (> 
2.2 m2) body surface area (BSA). Images of the BSA-adapted protocol show an 
equivalent coronary attenuation independent of individual BSA (top row), while 
differences in attenuation can be seen in the control group depending on individual 
BSA (bottom row). 
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Table 1a: Protocol for BSA-adapted contrast-material (CM) bolus and flow rate 
BSA (m2) CM bolus (ml) flow rate (ml/sec) 
< 1.70 40 3.5 
1.70 – 1.79 45 4.0 
1.80 – 1.94 60 4.0 
1.95 – 2.04 80 4.5 
2.05 – 2.14 80 5.0 
2.15 – 2.24 85 5.0 
2.25 – 2.49 95 5.0 
≥ 2.5 105 5.0 
 
CM contrast-material, BSA body surface area 
 
 
 
 
 
Table 1b: Protocol for BMI-adapted tube parameters (according to ref. 23)  
BMI (kg/m2) Tube voltage (kV) Tube current (mA) 
< 22.5 100 450 
22.5 - 25 100 500 
25 – 27.5 120 550 
27.5 – 30 120 600 
30 - 40 120 650 
> 40  120 700 
 
BMI body mass index 
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Table 2: Patient baseline characteristics 
 
 non-adapted scanning 
protocol (n = 80) 
BSA-adapted scanning 
protocol (n = 80) 
Female/male 21/59 12/68 
Age (years)  59±11 (34-82)  57±11 (31-85) 
BSA (m2) 1.980.17 (1.59-2.38) 1.980.15 (1.66-2.39 ) 
Weight (kg) 82±12 (55-115) 82±12 (60-118) 
Height (cm) 172±8 (156-193) 174±5 (149-183) 
Heart rate (bpm) 56±7 (36-74) 56±7 (40-72) 
 
BSA body surface area, bpm beats per minute  
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Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 19 
Figure 2 
 
 
